[Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
The effect of L-Thyroxine suppressive therapy (207.3 +/- 46.1 mcg/d) on lumbar spine bone density (BMD) was assessed in 51 patients thyroidectomized for carcinoma since 1 to 19 years (mean = 6 +/- 5.4 years); the bone densities of these patients were compared with those of 51 age sex weight-matched control subjects. Trabecular bone density was evaluated by single energy quantitative tomography. The vertebral BMD was not significantly different between the patients receiving suppressive doses of L-T4 and the control group (162.8 +/- 40.4 vs 162.7 +/- 39.8 mg/cm3). We found no relationship between the duration of L-Thyroxine therapy and BMD. Thus, doses of L-T4 sufficient for suppressing plasma thyroid stimulating hormone but no high enough for causing biochemical thyrotoxicosis have no harmful effect on trabecular bone mineral density.
Eulry
F
F
Service de Rhumatologie, Hôpital d'Instruction des Armées Begin, Saint-Mandé.
Bauduceau
B
B
Lechevalier
D
D
Magnin
J
J
Crozes
P
P
Flageat
J
J
Gautier
D
D
D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D013974:Thyroxine / Q000494:pharmacology / Q000627:therapeutic use*
D013974:Thyroxine
La densité osseuse dans le cancer différencié du corps thyroïde traité par opothérapie thyroïdienne freinatrice. Etude à propos de 51 observations.